+ Watch ZIOP
on My Watchlist
Good Q/Q numbers, charts and a dash of takeover speculation.
If you follow biopharma stocks, you've no doubt been to biopharma websites. In that case, you've seen the ubiquitous stock photo on the company home page showing the smiling individual, often elderly, often outdoors, clearly enjoying life. The idea, I'm sure, is to get you into the right frame of mind before reading their press releases. Don't believe the hype? Might as well punch that smiling old person in the face.Ziopharm isn't content to assault their visitors with one of these stock photos. Their homepage is a mosaic of dozens of pictures of smiling models who have absolutely no connection to their company. Drag your mouse over a picture ... and it lights up! Get a good look at these people who were never helped by Ziopharm's unapproved drugs which have never demonstrated any benefit in advanced clinical trials. Does it give you a warm and toasty feeling? Good. Now explore the website, and try not to be put off by the nauseating grey on black layout and ten point font.Ziopharm has been exhumed from recent lows of 1.6 with new enthusiasm about recently inlicensed pipeline compound Ad-RTS IL-12. All is forgiven regarding the serial destruction of the original pipeline of darinaparsin, indibulin, and most recently palifosfamide. After all, Ziopharm is now going to cure melanoma. Forgive my skepticism. Intrexon has been all over the the biopharma sector of late with partnerships with such stellar outfits as Soligenix, Fibrocell, and Synthetic Biologics. Compared to those monkeys, Ziopharm looks like a movie star. I don't see Intrexon as anyone's knight in shining armor, unless you're just looking for a reason to keep the lights on and pay management salaries for another four or five years.
A true speculative play with huge upside potential. With master investory RJ Kirk behind this security and from all accounts many promising developments. This could be the proverbial 5 bagger holy grail that FOOLS rarely see.
possible new technology
First review the released statements since 2009. Then read about what this company does. They research on eliminations of the existent cancer drugs side effects. This company works in drugs researching provided by Intrexon. If they become successful “many years away”, most likely the Intrexon will be the one profit from it. The stock is overpriced.
I might buy a few shares today.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions